Axsome Therapeutics Inc (AXSM)

HEALTH CARE: PHARMACEUTICALS
SIC: PHARMACEUTICAL PREPARATIONS

200 BROADWAY, 3RD FLOOR NEW YORK, NY 10038

Axsome Therapeutics, Inc. operates as a clinical stage biopharmaceutical company. The Company focuses on developing therapies for the management of pain, neurological disorders, and other central nervous system. Axsome Therapeutics serves patients worldwide.

Data based on most recent fiscal year report
Market Cap3.062 Billion Shares Outstanding34.51 Million Avg Volume1.948 Million
1-Yr BETA vs S&P TR1.015 Current Ratio1.41 Quick Ratio1.41
View SEC Filings from AXSM instead.

View recent insider trading info

Funds Holding AXSM (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding AXSM BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

COLEMAN MARK

  • Director
0 2020-03-17 4

TABUTEAU HERRIOT CHIEF EXECUTIVE OFFICER

  • Officer
  • Director
  • 10% Owner
0 2020-03-17 2

JEFFS ROGER

  • Director
0 2020-03-17 4

SAAD MARK E

  • Director
0 2020-03-17 3

PIZZIE NICK CHIEF FINANCIAL OFFICER

  • Officer
0 2020-03-17 4

MAREK DAVID C CHIEF COMMERCIAL OFFICER

  • Officer
0 2020-03-17 4

JACOBSON MARK L. CHIEF OPERATING OFFICER

  • Officer
0 2020-03-17 2

POTTER MYRTLE S

  • Director
12,480 2020-01-10 1

GOLUBIESKI JOHN CHIEF FINANCIAL OFFICER

  • Officer
0 2017-08-04 0

AMES CONSTANCE VICE PRESIDENT, FINANCE

  • Officer
0 2017-03-15 0

KAYE RANDALL CHIEF MEDICAL OFFICER

  • Officer
6,022 2015-12-23 0

ANTECIP CAPITAL LLC

  • 10% Owner
7,344,500 2015-11-19 0

Insider Transactions Last 60 Days

Reporting Owners Transaction Date Transaction Code Shares Share Price Acquired or Disposed Shares Owned Following Transaction Combined shares owned after filing Direct/Indirect Ownership 10b-5

TABUTEAU HERRIOT - Director - Officer - > 10% Owner CHIEF EXECUTIVE OFFICER

2020-03-17 A 168,776 a 168,776 0.00 direct

JACOBSON MARK L. - Officer CHIEF OPERATING OFFICER

2020-03-17 A 18,645 a 18,645 0.00 direct

MAREK DAVID C - Officer CHIEF COMMERCIAL OFFICER

2020-03-17 A 16,533 a 16,533 0.00 direct

JEFFS ROGER - Director

2020-03-17 A 4,496 a 4,496 0.00 direct

PIZZIE NICK - Officer CHIEF FINANCIAL OFFICER

2020-03-17 A 18,645 a 18,645 0.00 direct

JACOBSON MARK L. - Officer CHIEF OPERATING OFFICER

2020-03-17 A 60,880 a 60,880 0.00 direct

MAREK DAVID C - Officer CHIEF COMMERCIAL OFFICER

2020-03-17 A 53,984 a 53,984 0.00 direct

TABUTEAU HERRIOT - Director - Officer - > 10% Owner CHIEF EXECUTIVE OFFICER

2020-03-17 A 51,691 a 51,691 0.00 direct

PIZZIE NICK - Officer CHIEF FINANCIAL OFFICER

2020-03-17 A 60,880 a 60,880 0.00 direct

COLEMAN MARK - Director

2020-03-17 A 3,308 a 3,308 0.00 direct

SAAD MARK E - Director

2020-03-17 A 3,789 a 3,789 0.00 direct

Elevate your investments